Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Food Effects, and QT/QTc Interval Impact of VB19055 Tablets in Healthy Chinese Adult Subjects

NCT07254481 is registered in ClinicalTrials.gov with Zhejiang Yangli Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07254481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07254481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Food Effects, and QT/QTc Interval Impact of VB19055 Tablets in Healthy Chinese Adult Subjects
Lead sponsor
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 5, 2025
Completion date
July 31, 2026
Enrollment
86 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension